Marc Hasenfuss Investors Monthly editor, writer & columnist

Plague diary, week four: This entry has been abridged by the lockdown’s long weekend, but it was, I’m delighted to report, a short and spectacular session. Not only was the veggie patch not violated by the pesky primates (whereabouts, at the time of writing, unknown), but I had a rare rocket in the portfolio.

The share price of pharmaceuticals group Ascendis — where I have dosed up and down in recent weeks — took off like a Benzedrine addict being chased by a rabid Doberman...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now